section name header

Pronunciation ⬇

eye-soe-kar-BOKS-a-zid

Classifications ⬆ ⬇

Therapeutic Classification: antidepressants

Pharmacologic Classification: monamine oxidase inhibitors

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits the enzyme monoamine oxidase, resulting in an accumulation of various neurotransmitters (dopamine, epinephrine, norepinephrine, and serotonin) in the body.
Therapeutic effects:
  • Improved mood in depressed patients.

Pharmacokinetics ⬆ ⬇

Absorption: Unknown.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(antidepressant effect)

ROUTEONSETPEAKDURATION
POunknown3–6 wkunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: HYPERTENSIVE CRISIS, orthostatic hypotension

Derm: photosensitivity

EENT: blurred vision

GI: nausea, black tongue, constipation, diarrhea, dry mouth

GU: dysuria, sexual dysfunction, urinary incontinence, urinary retention

Neuro: dizziness, headache, akathisia, anxiety, ataxia, drowsiness, euphoria, insomnia, restlessness, SEIZURES, weakness

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Marplan

Code ⬆

NDC Code